SKAN Group AG
SIX:SKAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SKAN Group AG
Revenue
SKAN Group AG
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SKAN Group AG
SIX:SKAN
|
Revenue
CHf333.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Revenue
CHf695.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Revenue
CHf1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Revenue
CHf6.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Tecan Group AG
SIX:TECN
|
Revenue
CHf882.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Revenue
€391.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
SKAN Group AG
Glance View
SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.
See Also
What is SKAN Group AG's Revenue?
Revenue
333.3m
CHF
Based on the financial report for Dec 31, 2025, SKAN Group AG's Revenue amounts to 333.3m CHF.
What is SKAN Group AG's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was -8%. The average annual Revenue growth rates for SKAN Group AG have been 6% over the past three years , 12% over the past five years .